Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lauren S Jiménez-Kurlander, Gerald Behr, Nancy J Bunin, Ekaterina Doubrovina, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Leo Mascarenhas, Sarah Nikiforow, Richard J O'Reilly, Anita Price, Barry Shulkin, Ashok Srinivasan, Stephanie Suser, Justin Wahlstrom, Baodong Xing, Susan Prockop

Blood (2022) 140 (Supplement 1): 7524–7526.

https://doi.org/10.1182/blood-2022-157765

Published: 2022

Journal Articles

Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders

Benjamin Huang, MD, Christopher C. Dvorak, MD, Justin Wahlstrom, MD, Jimmy Hwang, PhD, Janel R Long-Boyle, PharmD, PhD, Morton Jerome Cowan, MD, Biljana N. Horn, MD

Blood (2014) 124 (21): 1155.

https://doi.org/10.1182/blood.V124.21.1155.1155

Published: 2014

Journal Articles

Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory Therapy After Allogeneic Hematopoietic Stem Cell (HSCT) For Acute Leukemia

Marie Ouachee-Chardin, MD, Christopher C. Dvorak, MD, Justin Wahlstrom, MD, Morton Jerome Cowan, MD, Janelle Facchino, PNP, Biljana N. Horn, MD

Blood (2013) 122 (21): 2082.

https://doi.org/10.1182/blood.V122.21.2082.2082

Published: 2013

Journal Articles

The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL

May Y. Szeto, B.A., Justin Wahlstrom, MD, Michelle L. Hermiston, MD, PhD

Blood (2012) 120 (21): 1355.

https://doi.org/10.1182/blood.V120.21.1355.1355

Published: 2012

Journal Articles

Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,

Justin Wahlstrom, MD, Kristin Ammon, MD, Christopher Esquivel, B.A., Jason Law, MD, Michelle L. Hermiston, MD, PhD

Blood (2011) 118 (21): 3490.

https://doi.org/10.1182/blood.V118.21.3490.3490

Published: 2011

NARROW

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders

Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory Therapy After Allogeneic Hematopoietic Stem Cell (HSCT) For Acute Leukemia

The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL

Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,

Email alerts

ASH Publications

American Society of Hematology

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Risk Factors for Graft Failure with Busulfan/Fludarabine-Based Conditioning in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Nonmalignant Disorders

Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory Therapy After Allogeneic Hematopoietic Stem Cell (HSCT) For Acute Leukemia

The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL

Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only